nomifensine has been researched along with Inappropriate GH Secretion Syndrome (Acromegaly) in 4 studies
Nomifensine: An isoquinoline derivative that prevents dopamine reuptake into synaptosomes. The maleate was formerly used in the treatment of depression. It was withdrawn worldwide in 1986 due to the risk of acute hemolytic anemia with intravascular hemolysis resulting from its use. In some cases, renal failure also developed. (From Martindale, The Extra Pharmacopoeia, 30th ed, p266)
nomifensine : An N-methylated tetrahydroisoquinoline carrying phenyl and amino substituents at positions C-4 and C-8, respectively.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Nomifensine, an inhibitor of endogenous catecholamine re-uptake, did not affect the growth hormone (GH) or prolactin levels in patients with acromegaly or hyperprolactinaemia." | 7.65 | Effects of nomifensine, an inhibitor of endogenous catecholamine re-uptake, in acromegaly, in hyperprolactinaemia, and against stimulated prolactin release in man. ( Cook, DB; Dewar, JH; Evered, DC; Gomez-Pan, A; Hall, R; Hildyard, A; Mora, B; Scanlon, MF; Weightman, DR, 1977) |
| " Nomifensine, an inhibitor of endogenous catecholamine re-uptake, did not affect the growth hormone (GH) or prolactin levels in patients with acromegaly or hyperprolactinaemia." | 3.65 | Effects of nomifensine, an inhibitor of endogenous catecholamine re-uptake, in acromegaly, in hyperprolactinaemia, and against stimulated prolactin release in man. ( Cook, DB; Dewar, JH; Evered, DC; Gomez-Pan, A; Hall, R; Hildyard, A; Mora, B; Scanlon, MF; Weightman, DR, 1977) |
| "Domperidone did not increase PRL in about a third of acromegalic patients, while TRH increased PRL in the all normoprolactinemic acromegalic patients." | 1.27 | Disturbed prolactin responses to dopamine-related substances in patients with acromegaly and hyperprolactinemia. ( Ibayashi, H; Ikuyama, S; Karashima, T; Kato, K; Muta, K; Sekiya, K, 1985) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ferrari, C | 1 |
| Romussi, M | 1 |
| Benco, R | 1 |
| Rampini, P | 1 |
| Mailland, F | 1 |
| Müller, EE | 1 |
| Cavagnini, F | 1 |
| Martinez-Campos, A | 1 |
| Maraschini, C | 1 |
| Giovannini, P | 1 |
| Novelli, A | 1 |
| De Leo, V | 1 |
| Scanlon, MF | 1 |
| Gomez-Pan, A | 1 |
| Mora, B | 1 |
| Cook, DB | 1 |
| Dewar, JH | 1 |
| Hildyard, A | 1 |
| Weightman, DR | 1 |
| Evered, DC | 1 |
| Hall, R | 1 |
| Sekiya, K | 1 |
| Karashima, T | 1 |
| Ikuyama, S | 1 |
| Muta, K | 1 |
| Kato, K | 1 |
| Ibayashi, H | 1 |
4 other studies available for nomifensine and Inappropriate GH Secretion Syndrome (Acromegaly)
| Article | Year |
|---|---|
Effect of dihydroergocristine administration on serum prolactin and growth hormone levels in normal, hyperprolactinaemic, and acromegalic subjects: further evidence for pituitary dopamine deficiency in these conditions.
Topics: Acromegaly; Adenoma; Adolescent; Adult; Amenorrhea; Dihydroergotoxine; Dopamine; Female; Growth Horm | 1983 |
Dynamic testing of prolactin and growth hormone secretion in patients with neuroendocrine disorders.
Topics: Acromegaly; Adolescent; Adult; Aged; Brain; D-Ala(2),MePhe(4),Met(0)-ol-enkephalin; Domperidone; Fem | 1984 |
Effects of nomifensine, an inhibitor of endogenous catecholamine re-uptake, in acromegaly, in hyperprolactinaemia, and against stimulated prolactin release in man.
Topics: Acromegaly; Adult; Female; Humans; Isoquinolines; Male; Nomifensine; Prolactin; Tyrosine | 1977 |
Disturbed prolactin responses to dopamine-related substances in patients with acromegaly and hyperprolactinemia.
Topics: Acromegaly; Adult; D-Ala(2),MePhe(4),Met(0)-ol-enkephalin; Domperidone; Female; Humans; Male; Middle | 1985 |